Effects on Quality of Life of a Telemonitoring Platform amongst Patients with Cancer (EQUALITE): A Randomized Trial Protocol

Vista sencilla de ítem
dc.contributor.authorMartínez, Felipe
dc.contributor.authorTaramasco, Carla
dc.contributor.authorEspinoza, Manuel
dc.contributor.authorAcevedo, Johanna
dc.contributor.authorGoic, Carolina
dc.contributor.authorNervi, Bruno
dc.date.accessioned2024-06-16T03:50:08Z
dc.date.available2024-06-16T03:50:08Z
dc.date.issued2024-04
dc.descriptionINDEXACIÓN: SCOPUS.
dc.description.abstractCancer, a pervasive global health challenge, necessitates chemotherapy or radiotherapy treatments for many prevalent forms. However, traditional follow-up approaches encounter limitations, exacerbated by the recent COVID-19 pandemic. Consequently, telemonitoring has emerged as a promising solution, although its clinical implementation lacks comprehensive evidence. This report depicts the methodology of a randomized trial which aims to investigate whether leveraging a smartphone app called Contigo for disease monitoring enhances self-reported quality of life among patients with various solid cancers compared to standard care. Secondary objectives encompass evaluating the app’s impact on depressive symptoms and assessing adherence to in-person appointments. Randomization will be performed independently using an allocation sequence that will be kept concealed from clinical investigators. Contigo offers two primary functions: monitoring cancer patients’ progress and providing educational content to assist patients in managing common clinical situations related to their disease. The study will assess outcomes such as quality of life changes and depressive symptom development using validated scales, and adherence to in-person appointments. Specific scales include the EuroQol Group’s EQ-5D questionnaire and the Patient Health Questionnaire (PHQ-9). We hypothesize that the use of Contigo will assist and empower patients receiving cancer treatment, which will translate to better quality of life scores and a reduced incidence of depressive symptoms. All analyses will be undertaken with the intention-to-treat principle by a statistician unaware of treatment allocation. This trial is registered in ClinicalTrials under the registration number NCT06086990. © 2024 by the authors.
dc.identifier.citationMethods and Protocols, Volume 7, Issue 2, April 2024, Article number 24
dc.identifier.doi10.3390/mps7020024
dc.identifier.issn2409-9279
dc.identifier.urihttps://repositorio.unab.cl/handle/ria/57618
dc.language.isoen
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.rights.licenseATTRIBUTION 4.0 INTERNATIONAL CC BY 4.0 Deed
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectadverse events
dc.subjectcancer
dc.subjectinternet
dc.subjectoncology
dc.subjectpatient surveillance
dc.subjectquality of life
dc.subjectsmartphone
dc.subjecttelemonitoring
dc.subjecttoxicity
dc.titleEffects on Quality of Life of a Telemonitoring Platform amongst Patients with Cancer (EQUALITE): A Randomized Trial Protocol
dc.typeArtículo
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
mps-07-00024.pdf
Tamaño:
942.02 KB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS.
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FM - Artículos de Revista